Business Context and Reporting Period
This Form 8-K Current Report was filed by Bausch Health Companies Inc. on December 8, 2025. The filing reports on the early results of debt exchange offers announced by the Company on the same date.
Key Financial Metrics and Transaction Details
The filing details a debt restructuring transaction involving the following metrics:
- Target Debt: Outstanding 4.875% Senior Secured Notes due 2028 and 11.00% Senior Secured Notes due 2028.
- New Issuance: Up to $1.6 billion aggregate principal amount of new 10.00% Senior Secured Notes due 2032.
- Issuer: 1261229 B.C. Ltd., an indirect wholly-owned subsidiary of Bausch Health.
- Reporting Time: Results reported as of 5:00 p.m. New York City time on December 8, 2025.
Note: The filing text does not provide specific values for revenue, profit, cash flow, margins, or total liquidity positions, as this report focuses solely on the debt exchange event.
Material Changes
The primary material change is the initiation of an exchange offer to replace existing senior secured notes with new notes having a longer maturity (2032) and a different interest rate (10.00%). The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
Management Commentary: The Company announced early results of the offers but did not include forward-looking guidance or specific outlook statements in this filing text.
Risks and Contingencies:
- Registration Status: The new notes are not registered under the U.S. Securities Act or Canadian prospectus requirements and are being offered only pursuant to specific exemptions.
- Legal Restrictions: No offer or sale will be made in jurisdictions where such actions would be unlawful.
- Non-Offer Status: This 8-K and the attached press release do not constitute an offer to sell or purchase securities.
Investor Verification Checklist
- Verify the final acceptance rates and total principal amount exchanged in the full results of the offer.
- Review the attached Exhibit 99.1 (Press Release) for specific details on the early results not included in the main text.
- Confirm the impact of the new 10.00% interest rate on future interest expense compared to the retired 4.875% and 11.00% notes.
- Assess the extension of debt maturity from 2028 to 2032 and its effect on the Company's liquidity profile.